Trials / Completed
CompletedNCT02722837
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOF/VEL | 400/100 mg FDC tablet administered orally once daily |
Timeline
- Start date
- 2016-04-04
- Primary completion
- 2017-06-26
- Completion
- 2017-09-13
- First posted
- 2016-03-30
- Last updated
- 2018-11-16
- Results posted
- 2018-07-17
Locations
15 sites across 2 countries: Russia, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02722837. Inclusion in this directory is not an endorsement.